secwatch.observer — SEC 8-K summary
======================================

Issuer:     Seres Therapeutics, Inc. (MCRB)
CIK:        0001609809
Form:       8-K
Filed at:   2025-01-10T23:59:59+00:00
Accession:  0001193125-25-004062
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Seres reports $31M cash, SER-155 biomarker data positive, FDA Breakthrough Therapy
--------------------------------------------------------------------------------

- Prelim cash $31M as of Dec 31, 2024; with Nestlé payments of ~$75M, cash runway into Q1 2026.
- SER-155 Phase 1b biomarker: significant decrease in fecal albumin (epithelial barrier integrity) vs placebo.
- FDA granted Breakthrough Therapy designation for SER-155 in allo-HSCT in Dec 2024.
- Briefing Book submitted for next registrational study; FDA feedback expected Q1 2025.
- SER-155 results accepted for oral presentation at TANDEM Meeting Feb 2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1609809/000119312525004062/0001193125-25-004062-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1609809/000119312525004062/d925391d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-004062

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer